It looks like you are using an older version of Internet Explorer which is not supported. We advise that you update your browser to the latest version of Microsoft Edge, or consider using other browsers such as Chrome, Firefox or Safari.

Biosimilars can help reduce the high cost of oncology medicines spending1,2

Oncology innovation is booming, but costly for the healthcare system2

US oncology medicines spending continues to rise

*Costs through 2026 are based on data reported by the IQVIA Oncology Link from April 2022. Costs beyond 2022 are projected growth based on a CAGR of 10.6% in the next 5 years.2

biosimilars create early and expanded patient access to life

Learn about ZIEXTENZO (pegfilgrastim-bmez), the long-acting G-CSF treatment option from Sandoz4

CAGR=compound annual growth rate; G-CSF=granulocyte colony-stimulating factor.


1. IQVIA Institute for Human Data Science. Global oncology trends 2018: innovation, expansion and disruption. Accessed November 28, 2021. 2. IQVIA Institute for Human Data Science. Global oncology trends 2022: outlook to 2026. Accessed November 21, 2022. 3. IQVIA Institute for Human Data Science. Global oncology trends 2019: therapeutics, clinical development and health system implications. Accessed November 21, 2022. 4. Socal M, Ballreich J, Chyr L, Anderson G. Biosimilar medications – savings opportunities for large employers. A report for ERIC – the ERISA Industry Committee. Department of Health Policy and Management. John Hopkins Bloomberg School of Public Health. March 2020. 5. Trautman H, Szabo E, James E, et al. Patient-Administered Biologic and Biosimilar Filgrastim May Offer More Affordable Options for Patients with Nonmyeloid Malignancies Receiving Chemotherapy in the United States: A Budget Impact Analysis from the Payer Perspective. J Manag Care Spec Pharm. 2019;25:94-101. 6. Puckrein G, et al. Sandoz biosimilar Zarxio (filgrastim-sndz) reduced out-of-pocket costs for Medicare patients with breast cancer versus the reference medicine. Poster presented at: San Antonio Breast Cancer Symposium (SABCS); December 7, 2018; San Antonio, TX. 7. McBride A, et al. Expanded access to cancer treatments from conversion to neutropenia prophylaxis with biosimilar filgrastim-sndz. Future Oncol. 2017;13:2285-2295. 8. ZIEXTENZO Prescribing Information. Sandoz Inc. March 2021.